SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Gilead CEO, When Asked If Co. Will Turn A Profit From Remdesivir, Notes Co. Currently At Beginning Of Lifecycle For Remdesivir, Says Will Be Investing Further In Drug

Benzinga · -